L3VLUP
ProSign in

BMRN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMRNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMRN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBMRNLLY
Q3 202012 holders, $3.0bn33 holders, $14.1bn
Q4 202012 holders, $3.7bn29 holders, $17.3bn
Q1 202110 holders, $3.1bn24 holders, $23.0bn
Q2 202111 holders, $3.4bn24 holders, $27.8bn
Q3 202114 holders, $3.0bn31 holders, $29.9bn
Q4 202114 holders, $3.4bn31 holders, $34.7bn
Q1 202219 holders, $3.0bn24 holders, $35.3bn
Q2 202221 holders, $2.9bn33 holders, $42.7bn
Q3 202225 holders, $3.1bn31 holders, $43.4bn
Q4 202226 holders, $4.0bn31 holders, $46.6bn
Q1 202320 holders, $3.3bn33 holders, $44.3bn
Q2 202318 holders, $2.9bn37 holders, $59.6bn
Q3 202318 holders, $2.9bn44 holders, $67.6bn
Q4 202322 holders, $4.1bn45 holders, $73.6bn
Q1 202419 holders, $3.6bn41 holders, $95.3bn
Q2 202416 holders, $3.3bn43 holders, $110bn
Q3 202416 holders, $3.0bn45 holders, $107bn
Q4 202414 holders, $3.0bn46 holders, $93.9bn
Q1 202516 holders, $3.3bn42 holders, $98.4bn
Q2 202516 holders, $2.5bn43 holders, $93.2bn
Q3 202516 holders, $2.3bn39 holders, $86.7bn
Q4 202521 holders, $2.4bn41 holders, $123bn
Q1 202615 holders, $2.6bn39 holders, $106bn
Q2 202612 holders, $2.2bn44 holders, $132bn
BMRN

Biomarin Pharmaceutical Inc

Holders
21
Reported value
$2.4bn
Buyers
24
Sellers
19

Breadth +5 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMRN (5)

Caxton Associates LLP, ExodusPoint Capital Management LP, Schonfeld Strategic Advisors LLC, Viking Global Investors LP, Voloridge Investment Management LLC

Only LLY (25)

AllianceBernstein LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Marshall Wace LLP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →